Radiolabeling, Characterization, And In Vitro Cell Culture Studies of Donepezil-Loaded Niosome Formulations For Brain Imaging
Makaleler > Tam Makale · 2024
Yazarlar: Emre ÖZGENÇ, Hande Aydın, Zeynep Ay Şenyiğit, Evren ATLIHAN GÜNDOĞDU
Fabad Journal of Pharmaceutical Sciences, Uluslararası, Scopus, 2024
DOI: 10.55262/fabadeczacilik.1385224
Özet
Dementia has posed a significant public health challenge for aging populations in developed countries for many years. Alzheimer's Disease (AD) is the most prevalent cause of dementia, marked by cognitive and behavioral irregularities resulting from cholinergic dysfunction, a progressive and irreversible neurodegenerative disorder. Restoring cholinergic neurotransmission can alleviate impaired cognitive and behavioral symptoms in AD patients. Donepezil (DNP) is an acetylcholinesterase inhibitor utilized to treat mild to moderate AD symptoms. Niosomes, non-ionic surfactant vesicles, present an array of benefits as drug delivery systems, including stability, non-immunogenicity, permeation potential, and controlled release ability. In this research, we prepared, characterized, radiolabeled with 99mTc, and evaluated DNP-loaded niosome formulations as radiopharmaceuticals for brain imaging agents. The findings suggest that this innovative radiopharmaceutical ([99mTc]Tc-formulation) has the potential to serve as a promising alternative imaging agent for neurological disorders.